Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal Therapy

Art Rastinehad, DO
Published: Thursday, Jun 02, 2016


Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.
 
Prostate is the last solid organ malignancy that is diagnosed by randomly sampling the gland, says Rastinehad.
 
A transperineal MR/TRUS fusion biopsy system has been developed that tracks the probe and needles with EM tracking. This technology has potential for application in transperineal focal therapy.
 
The system is FDA cleared for treatment, so oncologists can diagnosis and treat specific areas in the prostate. This may reduce the need for radiation and/or surgery.
 

Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.
 
Prostate is the last solid organ malignancy that is diagnosed by randomly sampling the gland, says Rastinehad.
 
A transperineal MR/TRUS fusion biopsy system has been developed that tracks the probe and needles with EM tracking. This technology has potential for application in transperineal focal therapy.
 
The system is FDA cleared for treatment, so oncologists can diagnosis and treat specific areas in the prostate. This may reduce the need for radiation and/or surgery.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x